Join Paid Clinical Trials for COPD in Canada

Paid Clinical Trials and Focus Groups by Category

All Categories ... Medical Conditions » ... COPD » ... Canada

Effects of Tiotropium on Breathing Capacity and Exercise Limitation in Early Stages of Chronic Obstructive Pulmonary Disease

Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: Placebo; Drug: Tiotropium
Sponsors: Boehringer Ingelheim Pharmaceuticals; Pfizer
Recruiting - verified March 2010
Eccentric Exercise Training as Novel Rehabilitation for Chronic Obstructive Pulmonary Disease (COPD)

Conditions: Pulmonary Disease, Chronic Obstructive; Bronchitis, Chronic; Emphysema
Intervention: Other: Eccentric exercise training
Sponsors: McGill University; McGill University Health Center
Recruiting - verified December 2009
To Assess the Long-term Safety, Tolerability and Efficacy of Aclidinium Bromide at Two Dose Levels in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) and Efficacy of Aclidinium Bromide in Patients With Moderate to Severe, Stable COPD

Condition: Chronic Obstructive Pulmonary Disease
Interventions: Drug: aclidinium bromide; Drug: aclidinium bromide
Sponsors: Forest Laboratories; Almirall, S.A.
Recruiting - verified February 2010
To Assess the Long-term Safety, Efficacy and Tolerability of Inhaled Aclidinium Bromide in the Treatment of Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)

Condition: Chronic Obstructive Pulmonary Disease
Interventions: Drug: Aclidinium bromide; Drug: Aclidinium bromide; Drug: Placebo
Sponsors: Forest Laboratories; Almirall, S.A.
Recruiting - verified February 2010
Determining Optimal Free Dose Combination of Tiotropium Bromide and BI 1744 CL in Chronic Obstructive Pulmonary Disease (COPD)

Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: olodaterol (BI 1744) low and placebo; Drug: olodaterol (BI 1744) low and low tio; Drug: olodaterol (BI 1744) high and placebo; Drug: olodaterol (BI 1744) low and medium tio; Drug: olodaterol (BI 1744) low and high tio; Drug: olodaterol (BI 1744) high and low tio; Drug: olodaterol (BI 1744) high and medium tio; Drug: olodaterol (B( 1744) high and high tio
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Effect of Treatment BI 1744 CL (5 and 10 Mcg) Versus Placebo on Exercise Endurance Time During Constant Work Rate Cycle Ergometry II

Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: Olodaterol (BI 1744); Drug: Olodaterol (BI 1744); Drug: Placebo
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Effect of Treatment BI 1744 CL (5 and 10 Mcg) Versus Placebo on Exercise Endurance Time During Constant Work Rate Cycle Ergometry I

Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: Olodaterol (BI 1744); Drug: Olodaterol (BI 1744); Drug: Placebo
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: FF/GW642444 Inhalation Powder; Drug: GW642444 Inhalation Powder
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: GW642444 Inhalation Powder; Drug: FF/GW642444 Inhalation Powder
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Study of the Effects of SCH 527123 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)(P05575AM1)

Condition: Chronic Obstructive Pulmonary Disease
Interventions: Drug: SCH 527123; Drug: Placebo
Sponsor: Schering-Plough
Recruiting - verified March 2010
Pathophysiological Mechanisms of Dyspnea and Activity-limitation in Mild Chronic Obstructive Pulmonary Disease (COPD)

Condition: Chronic Obstructive Pulmonary Disease
Interventions: Drug: Bronchodilator Agents; Drug: Normal saline; Device: Dead space breathing; Device: Room air breathing
Sponsors: Queen's University; Canadian Lung Association
Not yet recruiting - verified March 2010
Effect of Inhaled Fentanyl on Dyspnea and Exercise Tolerance in Chronic Obstructive Pulmonary Disease (COPD)

Condition: Chronic Obstructive Pulmonary Disease
Interventions: Drug: fentanyl; Drug: normal saline (placebo)
Sponsor: Queen's University
Recruiting - verified March 2010
Comparison of Indacaterol and Tiotropium on Lung Function and Related Outcomes in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Condition: Chronic Obstructive Pulmonary Disease
Interventions: Drug: Indacaterol 150 µg; Drug: Tiotropium
Sponsor: Novartis Pharmaceuticals
Recruiting - verified February 2010
Moxifloxacin Versus Amoxicillin Clavulanic Acid in Treatment of Acute Exacerbation of Chronic Bronchitis

Condition: Chronic Bronchitis
Interventions: Drug: Avelox (Moxifloxacin, BAY12-8039); Drug: Amoxicillin clavulanic acid
Sponsor: Bayer
Recruiting - verified March 2010
Theophylline in Chronic Obstructive Pulmonary Disease

Condition: COPD
Intervention: Drug: Theophylline
Sponsors: Ottawa Hospital Research Institute; Ontario Lung Association
Recruiting - verified March 2010

Join Paid Clinical Trials for COPD in Canada - Clinical Trials

Join Paid Clinical Trials for COPD in Canada

Paid Clinical Trials and Focus Groups by Category

Main Menu

Find Clinical Trials

Clinical Trial Locations

Clinical Trial Categories

Patient Recruiting...

Paid Clinical Trials